FMT(TM) Quantitative Tomographic Imaging Being Expanded to Four Fluorescent Channels to Enable Greater Data Ranges and Multiplexing of Disease Biomarkers In Vivo
VisEn Multi-Modality Imaging Adapter Series Launched to Enable Imaging, Co-Registration and Data Fusion Between FMT and CT, MR, Spect and PET
BEDFORD, Mass., April 20 /PRNewswire/ -- VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced that users of its FMT 2500 Quantitative Tomography Platform will soon be able to access four channels of quantitative fluorescent imaging -- 635 nm, 670 nm, 745 nm, and 790 nm -- allowing greater flexibility in imaging and multiplexing of VisEn’s fluorescent imaging agents in multiple disease pathways in vivo. VisEn also announced today that it has launched its proprietary line of FMT Multi-Modality Adaptors designed to enable researchers to readily combine FMT readouts with imaging results from complementary microCT, PET, MR and Spect platforms. The announcements were made during the AACR (American Association of Cancer Research) 100th Annual Meeting 2009, being held April 18-22, 2009 in Denver, CO.
FMT 2500 Four Channel Imaging Upgrade and System Available Summer 2009
The expanded FMT 2500 Four Channel offering will become available in the summer of 2009 and can be purchased as an upgrade to existing FMT 2500 systems, or as an added feature to a new FMT system. In addition to the standard wavelengths of 670 nm and 745 nm offered in the FMT 2500, VisEn will now offer customers FMT imaging in two new laser wavelengths: 635 nm and 790 nm. Upgrading the FMT 2500 from two to four channels to span a broader spectral fluorescence range from 650 - 850 nm allows researchers greater imaging and fluorescence quantification capability in vivo.
“This expanded range of multi-modality and multi-plexing in vivo imaging products will allow FMT 2500-equipped research and pharmaceutical scientists even greater capabilities in measuring and quantifying biomarkers, disease progression and therapeutic efficacy in vivo,” said Kirtland Poss, President and CEO of VisEn. “We could not be more pleased with how these technologies continue to expand translational research and drug development today.”
FMT 2500 Multi-Modality Adaptors Available Now
VisEn’s new line of FMT Multi-Modality imaging adapters enables research scientists to combine imaging approaches and to fuse data sets from both FMT and a second modality including MRI, CT, Spect or PET. This resulting integration of quantified FMT biomarker readouts with precise anatomic morphology provides users the unprecedented ability to measure and monitor disease pathways and therapeutic efficacy in vivo. Examples can been seen at: www.visenmedical.com/applications/multi-modality_imaging/index.html.
Four models are now available and allow for multi-modality imaging between FMT and each of the following modalities: Siemens Inveon(TM) (mu)PET/CT, Gamma Medica’s (mu)CT, Bruker’s (mu)MRI and GE’s (mu)CT.
The FMT 2500 is based upon VisEn’s proprietary Fluorescence Molecular Tomography (FMT) technology platform which enables researchers to rapidly and easily generate in vivo quantitative tomographic data by using three key steps: data generation, data normalization, and fluorescence tomographic reconstruction. The researcher is therefore able to quantify biological targets and fluorescent agents to the picomole in vivo and in real time. The system offers multiplexed imaging capabilities so users can measure, monitor, and compare multiple in vivo biologic targets, pathways or processes simultaneously using different fluorescence agents.
Find out more about both the expanded Four Channel FMT 2500 System and the Multi-Modality Adaptors at VisEn’s Booth #451 at AACR 2009 in Denver, at Booth #407 at Experimental Biology (EB) in New Orleans, or at www.visenmedical.com.
About VisEn Medical
VisEn’s in vivo fluorescence imaging technologies, including its Fluorescence Agent Portfolio and its Fluorescence Molecular Tomographic (FMT(TM)) Imaging Systems provide robust fluorescence molecular imaging performance in identifying, characterizing and quantifying ranges of disease biomarkers and therapeutic efficacy in vivo. VisEn’s FMT systems and agents are used by leading research institutions and pharmaceutical companies in applications including cancer research, inflammation, cardiovascular, skeletal and pulmonary disease. The Company also works with large pharmaceutical partners to design ranges of tailored molecular imaging agents and applications that are designed to their specific pre-clinical and clinical research areas. Additional information can be found at www.visenmedical.com.
CONTACT: Robert Sandler, SVP, Marketing, VisEn Medical Inc., O.
+1-647-350-1881, C. +1-416-274-8166, rsandler@visenmedical.com; or Peter
Steinerman, Principal, Steinerman Biomedical Comm., O. +1-516-374-3031, C.
+1-516-641-8959, PRSteinerman@aol.com
Web site: http://www.visenmedical.com/
